<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318694</url>
  </required_header>
  <id_info>
    <org_study_id>CDEB025A2301</org_study_id>
    <secondary_id>2010-022867-37</secondary_id>
    <nct_id>NCT01318694</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of alisporivir (ALV; DEB025) triple therapy
      [i.e., when added to peginterferon alfa-2a (PEG) and ribavirin (RBV)] to optimize treatment
      in treatment-naïve participants with hepatitis C virus (HCV) genotype 1 (GT1)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12)</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
    <description>SVR12 was defined as hepatitis C virus (HCV) RNA laboratory value below the level of quantification (&lt; LOQ; i.e., 25 IU/ml) 12 weeks after the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved SVR 24 Weeks After the End of Treatment (SVR24)</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
    <description>SVR24 was defined as HCV RNA laboratory value &lt; LOQ 24 weeks after the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Virologic Response (RVR) After 4 Weeks of Treatment (RVR4)</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>RVR4 was defined as serum HCV RNA &lt; LOQ after 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Early Virologic Response (EVR) After 12 Weeks of Treatment</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>EVR was defined as a ≥ 2 log10 decrease in HCV RNA or HCV RNA &lt; LOQ after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Early Virologic Response (pEVR) After 12 Weeks of Treatment</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>pEVR was defined as a ≥ 2 log10 decrease in HCV RNA and still detectable (≥ LOQ) after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Early Virologic Response (cEVR) After 12 Weeks of Treatment</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>cEVR was defined as serum HCV RNA &lt; LOQ after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR) From 4 to 12 Weeks of Treatment</measure>
    <time_frame>from 4 to 12 weeks of treatment</time_frame>
    <description>eRVR was defined as achieving RVR4 and maintaining HCV RNA &lt; LOQ until Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With End of Treatment Response (ETR) at Treatment End Within 48 Weeks</measure>
    <time_frame>at treatment end within 48 weeks</time_frame>
    <description>ETR was defined as serum HCV RNA &lt; LOQ at treatment end (completed or prematurely discontinued).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Alanine Aminotransferase (ALT) Abnormalities Within 48 Weeks</measure>
    <time_frame>within 48 weeks</time_frame>
    <description>ALT abnormalities were summarized as participants who had either:
ALT &gt; 2 x upper limit of normal (ULN) during the study and &gt; 2 x ULN at baseline
ALT &gt; 3 x ULN during the study and &gt; 2 x ULN at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 or 4 Anemia During Treatment Within 48 Weeks</measure>
    <time_frame>within 48 weeks</time_frame>
    <description>Grading was according to the Modified Division of Microbiology &amp; Infectious Diseases (DMID) Toxicity Tables (version 2.0).
Participants with multiple abnormalities were counted only once in the worst category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 or 4 Neutropenia During Treatment Within 48 Weeks</measure>
    <time_frame>within 48 weeks</time_frame>
    <description>Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 or 4 Thrombocytopenia During Treatment Within 48 Weeks</measure>
    <time_frame>within 48 weeks</time_frame>
    <description>Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1081</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):
Participants with a viral load below the level of detection (&lt; LOD) at Week 4 stop study treatment after 24 weeks
Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALV Placebo with PEG and RBV for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alisporivir</intervention_name>
    <description>ALV 200 mg soft gel capsules administered orally</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <other_name>DEB025</other_name>
    <other_name>ALV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>PEG 180 μg administered via subcutaneous (s.c.) injection once weekly</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_label>Treatment Arm D</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>PEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>RBV 200 mg tablets (weight-based dose: &lt; 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_label>Treatment Arm D</arm_group_label>
    <other_name>Copegus®</other_name>
    <other_name>RBV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALV Placebo</intervention_name>
    <description>ALV placebo soft gel capsules administered orally</description>
    <arm_group_label>Treatment Arm D</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Chronic HCV infection

          -  HCV genotype 1

          -  No previous treatment for hepatitis C infection

          -  Serum HCV RNA level ≥ 1000 IU/ml assessed by quantitative polymerase chain reaction or
             equivalent at screening, no upper limit

          -  Liver evaluation prior to baseline: liver biopsy within 3 years or Fibroscan within 6
             months

        Exclusion criteria:

          -  HCV genotype different from genotype 1 or co-infection with other HCV genotype

          -  Co-infection with Hepatitis B or HIV

          -  Any other cause of relevant liver disease other than HCV

          -  Presence or history of hepatic decompensation

          -  Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN), more than 1
             episode of elevated bilirubin (&gt; ULN) in past 6 months

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2002KDS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004BAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4n1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>v6z 2k5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Downsview</city>
        <state>Ontario</state>
        <zip>M3N 2Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bekescsaba</city>
        <zip>H-5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1126</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yangsan-si</city>
        <state>Gyeongsangnam-Do</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyunggi</city>
        <state>Kyeonggi</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pusan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chorzów</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kielce</city>
        <zip>25-317</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lódz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <state>District 1</state>
        <zip>050524</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <state>District 3</state>
        <zip>030317</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iasi</city>
        <state>Jud. Iasi</state>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iasi</city>
        <zip>700506</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119333</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.- Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chia-Yi</city>
        <zip>600</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yun-Lin</city>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <results_first_submitted>August 5, 2016</results_first_submitted>
  <results_first_submitted_qc>August 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2016</results_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Cyclophilin inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the 1580 patients screened at multiple global sites, 1081 (68.4%) were randomized and 499 (31.6%) discontinued from the study prior to randomization.</recruitment_details>
      <pre_assignment_details>Due to mis-randomization, four patients did not have a baseline visit and never started study medications. They were included in screened and randomized, but excluded from the Full Analysis Set and the Safety Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm A</title>
          <description>Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT)</description>
        </group>
        <group group_id="P2">
          <title>Treatment Arm B</title>
          <description>Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)</description>
        </group>
        <group group_id="P3">
          <title>Treatment Arm C</title>
          <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks</description>
        </group>
        <group group_id="P4">
          <title>Treatment Arm D</title>
          <description>ALV Placebo with PEG and RBV for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="270"/>
                <participants group_id="P3" count="268"/>
                <participants group_id="P4" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="270"/>
                <participants group_id="P3" count="265"/>
                <participants group_id="P4" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="268"/>
                <participants group_id="P3" count="265"/>
                <participants group_id="P4" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="225"/>
                <participants group_id="P4" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS), defined as all participants to whom study treatment was correctly assigned.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm A</title>
          <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
        </group>
        <group group_id="B2">
          <title>Treatment Arm B</title>
          <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
        </group>
        <group group_id="B3">
          <title>Treatment Arm C</title>
          <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
        </group>
        <group group_id="B4">
          <title>Treatment Arm D</title>
          <description>ALV Placebo with PEG and RBV for 48 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="274"/>
            <count group_id="B2" value="270"/>
            <count group_id="B3" value="265"/>
            <count group_id="B4" value="268"/>
            <count group_id="B5" value="1077"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="11.08"/>
                    <measurement group_id="B2" value="45.8" spread="11.95"/>
                    <measurement group_id="B3" value="45.5" spread="12.15"/>
                    <measurement group_id="B4" value="46.3" spread="11.53"/>
                    <measurement group_id="B5" value="45.9" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="154"/>
                    <measurement group_id="B5" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12)</title>
        <description>SVR12 was defined as hepatitis C virus (HCV) RNA laboratory value below the level of quantification (&lt; LOQ; i.e., 25 IU/ml) 12 weeks after the end of treatment.</description>
        <time_frame>12 weeks after the end of treatment</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12)</title>
          <description>SVR12 was defined as hepatitis C virus (HCV) RNA laboratory value below the level of quantification (&lt; LOQ; i.e., 25 IU/ml) 12 weeks after the end of treatment.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="265"/>
                <count group_id="O4" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                    <measurement group_id="O2" value="68.9"/>
                    <measurement group_id="O3" value="69.4"/>
                    <measurement group_id="O4" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved SVR 24 Weeks After the End of Treatment (SVR24)</title>
        <description>SVR24 was defined as HCV RNA laboratory value &lt; LOQ 24 weeks after the end of treatment.</description>
        <time_frame>24 weeks after the end of treatment</time_frame>
        <population>Participants in the Full Analysis Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved SVR 24 Weeks After the End of Treatment (SVR24)</title>
          <description>SVR24 was defined as HCV RNA laboratory value &lt; LOQ 24 weeks after the end of treatment.</description>
          <population>Participants in the Full Analysis Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="265"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5"/>
                    <measurement group_id="O2" value="69.0"/>
                    <measurement group_id="O3" value="68.3"/>
                    <measurement group_id="O4" value="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rapid Virologic Response (RVR) After 4 Weeks of Treatment (RVR4)</title>
        <description>RVR4 was defined as serum HCV RNA &lt; LOQ after 4 weeks of treatment.</description>
        <time_frame>after 4 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rapid Virologic Response (RVR) After 4 Weeks of Treatment (RVR4)</title>
          <description>RVR4 was defined as serum HCV RNA &lt; LOQ after 4 weeks of treatment.</description>
          <population>Participants in the Full Analysis Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="258"/>
                <count group_id="O4" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1"/>
                    <measurement group_id="O2" value="72.5"/>
                    <measurement group_id="O3" value="56.6"/>
                    <measurement group_id="O4" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Early Virologic Response (EVR) After 12 Weeks of Treatment</title>
        <description>EVR was defined as a ≥ 2 log10 decrease in HCV RNA or HCV RNA &lt; LOQ after 12 weeks of treatment.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Early Virologic Response (EVR) After 12 Weeks of Treatment</title>
          <description>EVR was defined as a ≥ 2 log10 decrease in HCV RNA or HCV RNA &lt; LOQ after 12 weeks of treatment.</description>
          <population>Participants in the Full Analysis Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                    <measurement group_id="O2" value="98.3"/>
                    <measurement group_id="O3" value="99.6"/>
                    <measurement group_id="O4" value="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Partial Early Virologic Response (pEVR) After 12 Weeks of Treatment</title>
        <description>pEVR was defined as a ≥ 2 log10 decrease in HCV RNA and still detectable (≥ LOQ) after 12 weeks of treatment.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Partial Early Virologic Response (pEVR) After 12 Weeks of Treatment</title>
          <description>pEVR was defined as a ≥ 2 log10 decrease in HCV RNA and still detectable (≥ LOQ) after 12 weeks of treatment.</description>
          <population>Participants in the Full Analysis Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Early Virologic Response (cEVR) After 12 Weeks of Treatment</title>
        <description>cEVR was defined as serum HCV RNA &lt; LOQ after 12 weeks of treatment.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Early Virologic Response (cEVR) After 12 Weeks of Treatment</title>
          <description>cEVR was defined as serum HCV RNA &lt; LOQ after 12 weeks of treatment.</description>
          <population>Participants in the Full Analysis Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="89.1"/>
                    <measurement group_id="O4" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Extended Rapid Virologic Response (eRVR) From 4 to 12 Weeks of Treatment</title>
        <description>eRVR was defined as achieving RVR4 and maintaining HCV RNA &lt; LOQ until Week 12.</description>
        <time_frame>from 4 to 12 weeks of treatment</time_frame>
        <population>Participants in the Full Analysis Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Extended Rapid Virologic Response (eRVR) From 4 to 12 Weeks of Treatment</title>
          <description>eRVR was defined as achieving RVR4 and maintaining HCV RNA &lt; LOQ until Week 12.</description>
          <population>Participants in the Full Analysis Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2"/>
                    <measurement group_id="O2" value="71.1"/>
                    <measurement group_id="O3" value="56.7"/>
                    <measurement group_id="O4" value="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With End of Treatment Response (ETR) at Treatment End Within 48 Weeks</title>
        <description>ETR was defined as serum HCV RNA &lt; LOQ at treatment end (completed or prematurely discontinued).</description>
        <time_frame>at treatment end within 48 weeks</time_frame>
        <population>Participants in the Full Analysis Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With End of Treatment Response (ETR) at Treatment End Within 48 Weeks</title>
          <description>ETR was defined as serum HCV RNA &lt; LOQ at treatment end (completed or prematurely discontinued).</description>
          <population>Participants in the Full Analysis Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                    <measurement group_id="O2" value="87.7"/>
                    <measurement group_id="O3" value="87.5"/>
                    <measurement group_id="O4" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Alanine Aminotransferase (ALT) Abnormalities Within 48 Weeks</title>
        <description>ALT abnormalities were summarized as participants who had either:
ALT &gt; 2 x upper limit of normal (ULN) during the study and &gt; 2 x ULN at baseline
ALT &gt; 3 x ULN during the study and &gt; 2 x ULN at baseline</description>
        <time_frame>within 48 weeks</time_frame>
        <population>Participants in the Safety Set, defined as having received at least one dose of study medication, with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Alanine Aminotransferase (ALT) Abnormalities Within 48 Weeks</title>
          <description>ALT abnormalities were summarized as participants who had either:
ALT &gt; 2 x upper limit of normal (ULN) during the study and &gt; 2 x ULN at baseline
ALT &gt; 3 x ULN during the study and &gt; 2 x ULN at baseline</description>
          <population>Participants in the Safety Set, defined as having received at least one dose of study medication, with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 2 x ULN and &gt; 2 x baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 3 x ULN and &gt; 2 x baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 or 4 Anemia During Treatment Within 48 Weeks</title>
        <description>Grading was according to the Modified Division of Microbiology &amp; Infectious Diseases (DMID) Toxicity Tables (version 2.0).
Participants with multiple abnormalities were counted only once in the worst category.</description>
        <time_frame>within 48 weeks</time_frame>
        <population>Participants in the Safety Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 or 4 Anemia During Treatment Within 48 Weeks</title>
          <description>Grading was according to the Modified Division of Microbiology &amp; Infectious Diseases (DMID) Toxicity Tables (version 2.0).
Participants with multiple abnormalities were counted only once in the worst category.</description>
          <population>Participants in the Safety Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 or 4 Neutropenia During Treatment Within 48 Weeks</title>
        <description>Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.</description>
        <time_frame>within 48 weeks</time_frame>
        <population>Participants in the Safety Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 or 4 Neutropenia During Treatment Within 48 Weeks</title>
          <description>Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.</description>
          <population>Participants in the Safety Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="7.2"/>
                    <measurement group_id="O4" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 or 4 Thrombocytopenia During Treatment Within 48 Weeks</title>
        <description>Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.</description>
        <time_frame>within 48 weeks</time_frame>
        <population>Participants in the Safety Set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm A</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm B</title>
            <description>Alisporivir (ALV) 400 mg BID with PEG and RBV for 24 or 48 weeks according to RGT</description>
          </group>
          <group group_id="O3">
            <title>Treatment Arm C</title>
            <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
          </group>
          <group group_id="O4">
            <title>Treatment Arm D</title>
            <description>ALV Placebo with PEG and RBV for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 or 4 Thrombocytopenia During Treatment Within 48 Weeks</title>
          <description>Grading was according to the DMID Toxicity Tables (version 2.0). Participants with multiple abnormalities were counted only once in the worst category.</description>
          <population>Participants in the Safety Set with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="264"/>
                <count group_id="O4" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="21.9"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm A</title>
          <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by an additional 23 or 47 weeks according to RGT</description>
        </group>
        <group group_id="E2">
          <title>Treatment Arm B</title>
          <description>Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)</description>
        </group>
        <group group_id="E3">
          <title>Treatment Arm C</title>
          <description>Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg QD for 47 weeks</description>
        </group>
        <group group_id="E4">
          <title>Treatment Arm D</title>
          <description>ALV Placebo with PEG and RBV for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryoadenitis acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Lipogranuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Craniopharyngioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="250" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="242" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="268"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>In April 2012, ALV and placebo were discontinued in all participants. Participants remained on PEG and RBV treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President Clinical Research &amp; Development</name_or_title>
      <organization>Debiopharm International S.A.</organization>
      <phone>4121 321 01 11</phone>
      <email>info-international@debiopharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

